New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034 on ClinicalTrials.gov · last registry update 2021-08-04

A small phase 4 — 13 participants, against a typical 75. The sponsor logged completion for 31 January 2017. Primary outcome, as filed: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Albert Einstein College of Medicine
Sponsor type: Other
Enrollment: 13
Started: 2010-12
Primary completion: 2017-01-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.